Identification of an Exosome-Related Signature for Predicting Prognosis, Immunotherapy Efficacy, and Tumor Microenvironment in Lung Adenocarcinoma

<div>Association of risk subgroup with therapy in LUAD patients. (a, b) Relationships between risk score and immune subtypes. (c, d) The survival status and immunotherapy reflection of patients in the high- and low-risk subgroups in two immunotherapy cohorts. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.</div>

Journal of Oncology

fig7

Figure 7

Figure 7: Identification of an Exosome-Related Signature for Predicting Prognosis, Immunotherapy Efficacy, and Tumor Microenvironment in Lung Adenocarcinoma 

Figure 7 | Identification of an Exosome-Related Signature for Predicting Prognosis, Immunotherapy Efficacy, and Tumor Microenvironment in Lung Adenocarcinoma 